Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis

K.E. Duhig, Paul T. Seed, J.E. Myers, R. Bahl, G. Bambridge, S. Barnfield, J. Ficquet, J.C. Girling, A. Khalil, A.H. Shennan, L.C. Chappell, R.M. Hunter

Research output: Contribution to journalArticlepeer-review


To calculate the cost‐effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.

Cost‐effectiveness analysis.

Eleven maternity units participating in the PARROT stepped‐wedge cluster‐randomised controlled trial.

Women presenting with suspected pre‐eclampsia between 20+0 and 36+6 weeks’ gestation.

Monte Carlo simulation utilising resource use data and maternal adverse outcomes.

Main outcome measures
Cost per maternal adverse outcome prevented.

Clinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost‐saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost‐saving of UK£2,891,196 each year across the NHS in England.

Clinical care with PlGF testing is associated with the potential for cost‐savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre‐eclampsia.
Original languageEnglish
Pages (from-to)1390-1398
Number of pages9
JournalBJOG: an international journal of obstetrics and gynaecology
Issue number11
Publication statusPublished - 17 Jul 2019


Dive into the research topics of 'Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis'. Together they form a unique fingerprint.

Cite this